30th Annual E.G. Scott Microbiology Symposium

30th Annual E.G. Scott Microbiology Symposium (Hybrid Event)

Tuesday October 10, 2023
8:15am-3:15pm (Registration opens at 7:45am)

Live Option: ChristianaCare Ammon Center, Main Auditorium
Virtual Option: Zoom Videoconferencing

REGISTRATION DEADLINE: October 4, 2023 (no late in-person registrations will be accepted)

Pre-registration is required!  
Please select the appropriate registration category and corresponding payment method for your desired attandance option.

The Zoom link & Conference information will be emailed on October 9, 2023.
Please check your spam & junk inbox if you do not see the email.
NOTE: Zoom link will NOT be sent if check payment and cost center information has not been received by the CC CME office.

$75.00 in-person registration fee
$65.00 virtual registration fee
**Cost Center transfers are for ChristianaCare employees only**
 

Checks MUST be received at least one week prior to the conference.

If paying by CHECK, please mail to:

Amy Minsker - CME Office
Lewis B. Flynn Medical Library - Ammon Education Building
Room 1E64C
4755 Ogletown-Stanton Road, Newark, DE 19718

Note: Indicate E.G.Scott Microbiology 2023 in the memo line

Questions: Contact Amy Minsker, CME Manager at amy.l.minsker@christianacare.org 

Event Overview

Join us at the Annual E.G. Scott Microbiology Symposium, where we tackle the pressing issue of mycobacterial testing methods. Gain invaluable insights as experts delve into the intricate landscape of mycobacterial identification, equipping you with the knowledge to explain and explore the array of available methods. Don't miss this educational event that empowers you to navigate the world of mycobacterial testing with confidence and precision.

Target Audience

This activity is intended for specialty physicians, primary care physicians, microbiology technologists, pharmacists, physician assistants, nurse practitioners, and clinical laboratory scientists.

Statement of Need

There is a need to understand the landscape of mycobacterial testing methods. There are updates, changes and nuances to antimicrobial susceptibility testing that impact management of mycobacterial infections. Novel fungal organism are causing infections and need to be detected by microbiologists and treated by clinicians.

Educational Objectives

Upon completion of this activity learners should be able to:

1. Explain available methods of mycobacterial identification.
2. Discuss methods and updates in phenotypic and genotypic testing of mycobacteria and understand changes and nuances in testing guidelines.
3. Explain the spectrum and category of fungal disease.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of Delaware and Christiana Care. The Medical Society of Delaware is accredited by the ACCME to provide continuing medical education for physicians.

It is the policy of the Medical Society of Delaware (MSD) to comply with the ACCME Standards for Commercial Support of Continuing Medical Education (CME). In keeping with these standards, all faculty participating in continuing medical education provided by MSD are expected to disclose to the activity audience any real or apparent conflicts of interest related to the content of their presentations.

Joint providership of CME by MSD in no way implies endorsement of any product or service. 

This activity is not supported by commercial funding.


 

Credit Designation Statement

The Medical Society of Delaware designates this live activity for a maximum of 5.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty and Disclosures

In accordance with the appropriate accrediting bodies, all planners, teachers, and authors with control over activity content are required to disclose to the provider any relevant financial relationships (those held by the planner or significant other, currently or within the last 24 months) with ineligible companies. Accredited providers are required to provide this information to learners before the start of an activity.

The following is a list of the faculty, along with any information they have disclosed regarding their relevant financial relationships.

Cynthia E. Flynn, MD (Planner, Activity Director) - has no relevant financial relationship(s) with ineligible companies to disclose.
Amy Minsker (Planner) - has no relevant financial relationship(s) with ineligible companies to disclose.
Julia Moeller MS, MLS(ASCP)CM (Planner, Moderator) - has no relevant financial relationship(s) with ineligible companies to disclose.
Lindsey Hardy MHA, MLS (ASCP) (Planner, Moderator) - has no relevant financial relationship(s) with ineligible companies to disclose.

April Bobenchik, PhD (Speaker) - received research funding for PI from Becton, Dickinson, TechLab, Quidel and BioMerieux - All of the relevant financial relationships listed for this individual have been mitigated. 

Christopher Doern, PhD (Speaker) - received honorarium from Shionogi and Quidel as role of speaker -  All of the relevant financial relationships listed for this individual have been mitigated.

Elitza S. Theel, PhD, D(ABMM) (Speaker) - received consultant fee from Roche Diagnostics, Euroimmun US and Serimmune Inc. as Advisory Board member - All of the relevant financial relationships listed for this individual have been mitigated.

Reeti Khare, PhD (Speaker) - has a 'Lab contract research' with Insmed, Spero Therapeutics, AN2 Therapeutics, Paratek Pharmaceuticals, and Mannkind. Received Lab grant funding from Illumina as principal investigator - Generic summary of available NTM therapeutics. No specific discussion of any therapeutics. All of the relevant financial relationships listed for this individual have been mitigated.

Sean Zhang, MD, PhD, D(ABMM) (Speaker) - received Research funds for PI from IMMY Dx, Applied BioCode, Scanogene, Pearl Dx, KARIUS, and Vela Dx. Received an honorarium from T2 Biosystems for SAB.  All of the relevant financial relationships listed for this individual have been mitigated.

Disclaimer

All information contained within this activity is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained in this educational activity. No single reference or service can take the place of medical training, education and experience. This educational activity does not define a standard of care, nor is it intended to dictate an exclusive course of management. This information should not substitute for a visit or consultation with a health care provider.

Technical Requirements

This activity is best experienced using the most current browser of Firefox, Chrome, Safari, or Microsoft Edge. For all activities featuring audio you must have a sound card and speakers. To view graphic images and references that appear in separate "pop-up" windows, you must have JavaScript and session cookies enabled on your computer. Adobe Acrobat Reader may be required for certain activities.

Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.